SWEET ON THESE SWEETS

Houston bakery startup dishes out healthy, low-calorie treats

ChipMonk Bakery has seen a growth in their healthy cookie business since the beginning of the pandemic. Photo courtesy of ChipMonk Baking

A Houston bakery is helping Houstonians satisfy their sweet tooth and while also counting their calories. ChipMonk Baking, a local, mail-order bakery, has seen significant growth since the start of the coronavirus pandemic as people look for healthier snacks than what they might find in a typical grocery store.

Founded by David Downing and Jose Hernandez, ChipMonk makes cookies, brownie bites, and other snacks using monk fruit and allulose, a low-calorie (0.4 calories per gram) rare sugar that's found naturally in foods such as raisins, dried figs, and kiwi. Hernandez began developing ChipMonk's recipes to satisfy his taste for cookies after being diagnosed with type-2 diabetes.

"We've refined these recipes and now offer numerous different cookies, dry mixes, and brownie bites which all taste delicious and won't spike your blood sugar," Hernandez says in a statement. "While they're great for people with diabetes, Celiac disease, or those who follow a keto diet, anyone who tries them will enjoy the taste and texture."

Jose Hernandez and David Downing founded ChipMonk Bakery. Photo courtesy of ChipMonk Baking

ChipMonk offers all the usual flavors — white chocolate-macadamia, chocolate chip, lemon, snickerdoodle, etc. — as well as dry mixes for those who want to bake at home. Recently, the company introduced red velvet brownie bites that use gluten-free sunflower seed flower. All of these products, as well as sample boxes, are available via ChipMonk's website; the company does not have a brick-and-mortar storefront.

Based on samples sent to CultureMap, the cookies have a chewy, slightly under-baked texture and a mild sweetness that's similar in flavor and appearance to cookies without their low-carb credentials.

Business has grown steadily over the its first year, according to the company, which has it looking to move from a shared commercial kitchen into its own space. Slated to open this summer, the dedicated bakery would allow Downing and Hernandez to expand both their offerings and the number of people they employ.

"We've received extremely positive feedback from our customers who appreciate having delicious, low-carb treats to enjoy while at home during this difficult time," Downing says. "We're seeing more and more people order for themselves as well as sending our products to friends, relatives, and co-workers."

------

This article originally ran on CultureMap.

Trending News

Building Houston

 
 

Allterum Therapeutics Inc., a portfolio company of Fannin Innovation Studio, is using the funds to prepare for clinical trials. Photo via Getty Images

Allterum Therapeutics Inc. has built a healthy launchpad for clinical trials of an immunotherapy being developed to fight a rare form of pediatric cancer.

The Houston startup recently collected $1.8 million in seed funding through an investor group associated with Houston-based Fannin Innovation Studio, which focuses on commercializing biotech and medtech discoveries. Allterum has also brought aboard pediatric oncologist Dr. Philip Breitfeld as its chief medical officer. And the startup, a Fannin spinout, has received a $2.9 million grant from the Cancer Prevention Research Institute of Texas.

The funding and Breitfeld's expertise will help Allterum prepare for clinical trials of 4A10, a monoclonal antibody therapy for treatment of cancers that "express" the interleukin-7 receptor (IL7R) gene. These cancers include pediatric acute lymphoblastic leukemia (ALL) and some solid-tumor diseases. The U.S. Food and Drug Administration (FDA) has granted "orphan drug" and "rare pediatric disease" designations to Allterum's monoclonal antibody therapy.

If the phrase "monoclonal antibody therapy" sounds familiar, that's because the FDA has authorized emergency use of this therapy for treatment of COVID-19. In early January, the National Institute of Allergy and Infectious Diseases announced the start of a large-scale clinical trial to evaluate monoclonal antibody therapy for treatment of mild and moderate cases of COVID-19.

Fannin Innovation Studio holds exclusive licensing for Allterum's antibody therapy, developed at the National Cancer Institute. Aside from the cancer institute, Allterum's partners in advancing this technology include the Therapeutic Alliance for Children's Leukemia, Baylor College of Medicine, Texas Children's Hospital, Children's Oncology Group, and Leukemia & Lymphoma Society.

Although many pediatric patients with ALL respond well to standard chemotherapy, some patients continue to grapple with the disease. In particular, patients whose T-cell ALL has returned don't have effective standard therapies available to them. Similarly, patients with one type of B-cell ALL may not benefit from current therapies. Allterum's antibody therapy is designed to effectively treat those patients.

Later this year, Allterum plans to seek FDA approval to proceed with concurrent first- and second-phase clinical trials for its immunotherapy, says Dr. Atul Varadhachary, managing partner of Fannin Innovation Studio, and president and CEO of Allterum. The cash Allterum has on hand now will go toward pretrial work. That will include the manufacturing of the antibody therapy by Japan's Fujifilm Diosynth Biotechnologies, which operates a facility in College Station.

"The process of making a monoclonal antibody ready to give to patients is actually quite expensive," says Varadhachary, adding that Allterum will need to raise more money to carry out the clinical trials.

The global market for monoclonal antibody therapies is projected to exceed $350 billion by 2027, Fortune Business Insight says. The continued growth of these products "is expected to be a major driver of overall biopharmaceutical product sales," according to a review published last year in the Journal of Biomedical Science.

One benefit of these antibody therapies, delivered through IV-delivered infusions, is that they tend to cause fewer side effects than chemotherapy drugs, the American Cancer Society says.

"Monoclonal antibodies are laboratory-produced molecules engineered to serve as substitute antibodies that can restore, enhance or mimic the immune system's attack on cancer cells. They are designed to bind to antigens that are generally more numerous on the surface of cancer cells than healthy cells," the Mayo Clinic says.

Varadhachary says that unlike chemotherapy, monoclonal antibody therapy takes aim at specific targets. Therefore, monoclonal antibody therapy typically doesn't broadly harm healthy cells the way chemotherapy does.

Allterum's clinical trials initially will involve children with ALL, he says, but eventually will pivot to children and adults with other kinds of cancer. Varadhachary believes the initial trials may be the first cancer therapy trials to ever start with children.

"Our collaborators are excited about that because, more often than not, the cancer drugs for children are ones that were first developed for adults and then you extend them to children," he says. "We're quite pleased to be able to do something that's going to be important to children."

Trending News